Carolyn L Friel

US Patent:

8173628, May 8, 2012

Filed:

Oct 19, 2007

Appl. No.:

11/975727

Inventors:

Robert N. Hanson - Newton MA, US
Carolyn Friel - Holden MA, US
Choon Young Lee - Mount Pleasant MI, US

Assignee:

Northeastern University - Boston MA

International Classification:

A61K 31/56

US Classification:

514182

Abstract:

The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hormone-responsive disorder. In an aspect of the invention, such treatments include therapeutic compositions comprising novel steroidal antiestrogen and antiandrogen compounds. In a preferred aspect, such a novel compound of the present invention has an address and a message component, which are made into a single composite entity for more aggressive intervention and effective treatment of hormone-responsive disorders, thereby prolonging the disease-free interval for the patient and reducing a number of side effects.

US Patent:

20040002484, Jan 1, 2004

Filed:

Dec 4, 2002

Appl. No.:

10/297310

Inventors:

Robert Hanson - Newton MA, US
Carolyn Friel - Boston MA, US
Choon Lee - Boston MA, US

International Classification:

A61K031/58
C07J017/00
C07J009/00
A61K031/573

US Classification:

514/179000, 540/117000, 552/553000, 514/176000

Abstract:

The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hormone-responsive disorde. In an embodiment of the invention, such treatments include therapeutic compositions comprising novel steroidal antiestrogen and antiandrogen compounds. In a preferred embodiment, such a novel compound of the present invention has an address and a message component, which are made into a single composite entity for more aggressive intervention and effective treatment of hormone-responsive disorders, thereby prolonging the disease-free interval for the patient and reducing a number of side effects.

US Patent:

20060148773, Jul 6, 2006

Filed:

Mar 7, 2006

Appl. No.:

11/369582

Inventors:

Robert Hanson - Newton MA, US
Carolyn Friel - Boston MA, US
Choon Lee - Boston MA, US

International Classification:

C07J 43/00
A61K 31/58
A61K 31/56
C07J 9/00

US Classification:

514176000, 514182000, 540107000, 552553000

Abstract:

The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hormone-responsive disorder. In an embodiment of the invention, such treatments include therapeutic compositions comprising novel steroidal antiestrogen and antiandrogen compounds. In a preferred embodiment, such a novel compound of the present invention has an address and a message component, which are made into a single composite entity for more aggressive intervention and effective treatment of hormone-responsive disorders, thereby prolonging the disease-free interval for the patient and reducing a number of side effects.